Description
OVERVIEWProduct overview
TB-500 is a synthetic peptide based on the active region of thymosin beta-4, a small protein found in most mammalian cells and one of the principal actin-sequestering molecules in the cytoplasm.
Because actin dynamics underpin how cells change shape and move, thymosin beta-4 and its fragments appear widely in preclinical literature on wound closure, corneal repair, cardiac injury models and dermal healing.
Findings to date come from cell culture and animal work. TB-500 is not a licensed medicine in Ireland, the United Kingdom or the European Union.
SUPPLY IN IRELANDTB-500 (Thymosin Beta-4) Ireland — supplied to research laboratories
Research groups across Ireland buy TB-500 (Thymosin Beta-4) from Kensington Laboratories as a lyophilised TB-500 (Thymosin Beta-4) peptide, released only against a batch-matched certificate of analysis. Every vial of high purity TB-500 (Thymosin Beta-4) is verified by HPLC and LC-MS before it leaves the facility, so laboratories ordering TB-500 (Thymosin Beta-4) in Ireland receive material with documented purity and identity.
Laboratory TB-500 (Thymosin Beta-4) is packed for controlled storage and sent by tracked delivery in 3–5 days to Dublin, Cork, Galway, Limerick and the rest of Ireland. Delivery costs €9.90 per order. Teams planning TB500(ThymosinBeta4) research can review the specifications, certificate of analysis and reference list on this page before ordering.
Institutions searching for TB-500 (Thymosin Beta-4) peptide suppliers in Ireland typically compare purity, batch documentation and delivery times. Each of those is published here: a 99% HPLC purity specification, a certificate matched to the batch code on your vial, and tracked delivery in 3–5 days.
TB-500 (Thymosin Beta-4) is supplied strictly for laboratory research use only. It is not a medicine and is not for human or veterinary consumption.
SPECIFICATIONSProduct specifications
- Purity: ≥ 99% (HPLC)
- Appearance: White lyophilised powder
- Quantity: 10 mg or 5 mg per vial
- CAS number: 77591-33-4
- Peptide class: Synthetic fragment of the naturally occurring thymosin beta-4 protein
- Also known as: Thymosin beta-4 fragment, Tβ4
- Solubility: Soluble in bacteriostatic or sterile water
- Storage temperature: Store at 2–8°C; long-term −20°C, protected from light
- Shelf life: 24 months lyophilised; 30 days reconstituted at 2–8°C
- Manufacturing standard: ISO 9001 facility, GMP-aligned solid-phase synthesis
- Batch information: Batch number and expiry printed on every vial label
RESEARCHResearch overview
The following summary is provided for educational and scientific context only. It describes what has been observed in published laboratory and animal studies and does not represent established clinical outcomes, medical advice or a claim of efficacy in humans.
Background
TB-500 is a synthetic peptide based on the active region of thymosin beta-4, a small protein found in most mammalian cells and one of the principal actin-sequestering molecules in the cytoplasm.
Because actin dynamics underpin how cells change shape and move, thymosin beta-4 and its fragments appear widely in preclinical literature on wound closure, corneal repair, cardiac injury models and dermal healing.
Findings to date come from cell culture and animal work. TB-500 is not a licensed medicine in Ireland, the United Kingdom or the European Union.
Current research areas
Published investigation clusters around a small number of biological themes. Each remains experimental and none has been established as a therapeutic effect in humans.
- Actin sequestration and cytoskeletal remodelling in cultured cells
- Keratinocyte and endothelial cell migration in wound-closure assays
- Corneal and dermal repair models
- Cardiac and skeletal muscle injury models
- Angiogenesis and vessel sprouting endpoints
Scientific context and proposed mechanisms
Thymosin beta-4 binds monomeric G-actin and regulates the pool available for filament assembly, which study authors link to the changes in cell motility reported in migration assays.
Several groups have additionally described effects on inflammatory signalling and on vascular endothelial cell behaviour, though the receptor biology of the peptide remains poorly defined.
Interpreting the evidence
Most published work in this area uses cell culture or rodent models with small group sizes and short observation windows. Independent replication varies considerably between compounds, and results are sensitive to species, route, dose and endpoint.
There is no regulatory-approved human protocol for this compound. Any laboratory protocol should be defined by the model under study, institutional ethical approval, appropriate controls and predefined endpoints.
References
CERTIFICATE OF ANALYSISIndependent batch testing
Every released batch is independently tested. Match the batch number on the vial to the certificate published online.
- Batch number
- KL-TB500THYMO-2408A
- Testing laboratory
- Colmaric Analyticals
- Date tested
- 21 July 2026
- Reported purity
- 99.54%
- Method
- RP-HPLC with UV detection at 214 nm, confirmed by LC-MS
